<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371912">
  <stage>Registered</stage>
  <submitdate>29/11/2016</submitdate>
  <approvaldate>1/12/2016</approvaldate>
  <actrnumber>ACTRN12616001657415</actrnumber>
  <trial_identification>
    <studytitle>A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects</studytitle>
    <scientifictitle>A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects</scientifictitle>
    <utrn>U1111-1190-0073 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adenovirus</healthcondition>
    <healthcondition>cytomegalovirus</healthcondition>
    <healthcondition>smallpox</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4 cohorts
Intravenous (IV) brincidofovir (BCV) 10mg or IV Placebo, single dose-6 active and 2 placebo
IV BCV 25mg or IV Placebo, single dose-6 active and 2 placebo
IV BCV 50mg or IV Placebo, single dose-9 active and 3 placebo
IV BCV 100mg or IV Placebo, single dose-9 active and 3 placebo

Dose escalation will be based on safety, tolerability, and pharmacokinetics of each cohort.  A safety and PK review by the Chimerix Study Team and the Principal Investigator (PI) will occur prior to escalation to the next dose level.

</interventions>
    <comparator>IV Placebo D5W Solution, single dose</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate the safety and tolerability following single dose escalating doses of BCV administered IV in healthy adult subjects.

Clinical and laboratory safety parameters including: adverse events (AE's), absolute and changes over time of hematology, clinical chemistry, urinalysis, vital signs, and ECG intervals
</outcome>
      <timepoint>Adverse Events (AEs), vital signs, clinical and laboratory safety assessments: At Screening Day -28, Days -1, 1, 2, 3, 4, 5, 8, 10, and Follow Up Day 14

Hematology, serum chemistry, urinalysis Screening Day -28, Days -1, 3, 5, 8, and Follow Up Day 14

ECG Assessments: On Day 1: pre-dose (within 15 minutes prior to start of infusion), 2 (end of infusion), 3, 4, 6, 8, 10, 12, 14, 16, and 24 hours post start of infusion. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize plasma BCV and CDV PK, and intracellular (peripheral blood mononuclear cells {PBMCs}) BCV and CDV-PP PK following single escalating doses of BCV administered IV in healthy adult subjects

Plasma BCV and CDV Cmax, Tmax, AUClast, AUCinf, %AUCextrap, Clast, Tlast, t1/2, CL (BCV only), Vss (BCV only)</outcome>
      <timepoint>Blood will be collected for determination of plasma BCV and CDV concentrations during each period as follows:
Subjects receiving BCV IV:  pre-dose (within 15 minutes prior to start of infusion) and at 2 (end of infusion), 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96, and 168 hours post start of infusion.
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>non-child bearing potential
willing and able to provide written informed consent
non-tobacco/non-nicotine user in the past 6 months
body weight no greater than 50kg
BMI from 18-32 kg/m
no significant medical history
males cannot donate sperm during participation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>child bearing potential 
 investigational drug or clinical study in the past 30 days
had any infection within the past 2 weeks
history of  history chronic liver disease
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>29/11/2016</actualstartdate>
    <anticipatedenddate>17/03/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Chimerix, Inc</primarysponsorname>
    <primarysponsoraddress>2505 Meridian Parkway
Suite 100
Durham, NC 27713
USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Chimerix, Inc</fundingname>
      <fundingaddress>2505 Meridian Parkway
Suite 100 
Durham NC 27713</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is the first clinical study administering a new intravenous formulation of BCV. BCV has been studied in hundreds of patients as an oral formulation for the treatment of adenovirus and for the treatment and prevention of  cytomegalovirus following stem cell transplantation.  This first IV BCV study will investigate the safety and tolerability following  single escalating doses to healthy subjects to observe how the new formulation compares to the oral formulations.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington 
6011</ethicaddress>
      <ethicapprovaldate>17/11/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Christopher J. Wynne</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011
</address>
      <phone>+ 64 3 372 9477</phone>
      <fax />
      <email>mark@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Mark Warner</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011</address>
      <phone>+ 64 3 372 9477</phone>
      <fax />
      <email>mark@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Maggie Anderson</name>
      <address>2505 Meridian Parkway
Suite 100
Durham NC 27713
USA</address>
      <phone>+ 1 919-313 2971</phone>
      <fax />
      <email>manderson@chimerix.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Donella Colville</name>
      <address>2505 Meridian parkway
Suite 100
Durham, NC 27713</address>
      <phone>011 919 972 7117</phone>
      <fax />
      <email>dcolville@chimerix.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>